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Abstract
An accurate understanding of the changes in height and weight of children with
age is critical to the development of models predicting drug concentrations in
children (i.e., physiologically-based pharmacokinetic models). However, curves
describing the growth of a typical population of children may not accurately characterize growth of children with various conditions, such as obesity. Therefore,
to develop height and weight versus age growth curves for youth who were
diagnosed with type 2 diabetes, we extracted data from electronic medical records. Robust nonlinear models were parameterized to the equations describing
height and weight versus age as defined by the Centers for Disease Control and
Prevention (CDC). CDC z-scores were calculated using an internal program. The
growth curves and z-scores were compared to CDC norms. Youth with type 2
diabetes were increasingly heavier than CDC norms from early childhood. Except
for a period around puberty, youth with type 2 diabetes were, on average, shorter
than CDC norms, resulting in shorter average adult height. Deviations in growth
were apparent in youth who develop type 2 diabetes; such deviations may be expected for other conditions as well, and disease-specific growth curves should be
considered during development of model-informed drug development for pediatric conditions.
Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?
The Centers for Disease Control and other agencies have developed growth
curves that represent typical children, but they do not extend beyond the 97th
percentile. The growth of many children with type 2 diabetes is therefore not
represented by these curves.
WHAT QUESTION DID THIS STUDY ADDRESS?
How does the height and weight of children who are diagnosed with type 2 diabetes change with age relative to a population of typically developing children?
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medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
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WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE?
Children who develop type 2 diabetes have growth patterns that deviate from the
norm.
HOW MIGHT THIS CHANGE CLINICAL PHARMACOLOGY OR
TRANSLATIONAL SCIENCE?
Given that physiologically-based pharmacokinetic scaling factors, such as liver
volume, are based on body surface area, which is, itself, derived from height and
weight, disease-specific growth curves should be considered for modeling and
simulation of dosing for pediatric drug development and clinical applications.

I N T RO DU CT ION
Physiologically-based pharmacokinetic (PBPK) models
are systems-based simulation tools that can help predict
pharmacokinetics in a population for which studies have
not yet been conducted, or for whom data are largely
unavailable. These models can be particularly helpful in
children, for whom large scale clinical trials can be challenging to implement.1 PBPK models integrate physiological and anatomic information for the population of
interest with physicochemical information for the drug.
Some physiological processes, such as hepatic drug clearance, trend with patient size, and equations have been developed to provide estimates of corresponding anatomic
features, such as liver volume, as a function of body size to
assist with extrapolation of in vitro enzyme activity to in
vivo clearance.2,3 Because children continuously grow and
develop during childhood, incorporation of growth curves
into these PBPK models is critical for accurately simulating pharmacokinetics across the pediatric age range.
Pediatric growth trajectories have been incorporated
into PBPK models, but these are largely representative of
healthy-weight children and do not accurately capture the
obesity epidemic of the 21st century.4,5
In 2016, over 340 million children worldwide, aged 5 to
18 years, met the World Health Organization (WHO) body
mass index (BMI) criteria for overweight/obesity. By 2019,
38 million more children under the age of 5 years were
diagnosed with overweight or obesity.6 These children are
at the top of, or exceed, the growth trajectories predicted
by the standard pediatric growth curves developed by the
Centers for Disease Control and Prevention (CDC) or the
WHO. This growing population of children with overweight or obesity is also at highest risk for comorbidities
that require management with medications, such as type
2 diabetes mellitus (T2DM). The efficacy of medications
used to treat T2DM in children varies substantially7 and
warrants further study. Yet, it is difficult to recruit and
retain youth with T2DM in clinical studies,8 therefore,
PBPK can be a useful tool in supplementing or simulating

clinical studies for this patient population. We, therefore,
developed and evaluated growth curves specific to children who develop T2DM, most of whom have overweight/
obesity. These modified growth curves are intended to be
used as population-specific scaling factors to enhance the
accuracy of PBPK models that simulate the pharmacokinetics of drugs used to treat children with T2DM (e.g.,
metformin). This population-specific modification to pediatric PBPK models is of particular importance given the
challenges associated with recruitment of children into
T2DM-drug studies that, in turn, may limit the availability
of robust, prospective pharmacokinetic data in this vulnerable and growing pediatric population.8

METHODS
Dataset
Height, weight, age, and sex for children 2–18 years of
age were extracted from an institutional review board-
approved deidentified dataset of visits to providers at
Children’s Mercy Kansas City, a Midwest tertiary pediatric
health system with hospitals and clinics located in Kansas
and Missouri. Data were from visits at Children’s Mercy
Clinics recorded between January 1, 2010 and August 24,
2016. Additionally, for some patients with data recorded in
2010 or later, data as early as May 30, 1997 was converted
from an older system. Extracted data included visits before and/or after T2DM diagnosis based on International
Classification of Disease (ICD)-9 or ICD-10 codes (e.g.,
ICD-9: 250.00, etc.). Children with a diagnosis of type 1
diabetes were excluded. Electronic health record-reported
height less than 12 or greater than 96 inches, weight = 0 or
greater than 600 pounds, and/or BMI less than 7 or greater
than 80 kg/m2 were also excluded. Whereas we primarily
expect that BMIs greater than 80 kg/m2 are due to measurement or data entry error, we do rarely see patients
above these BMI limits. Therefore, we additionally evaluated each of these 13 excluded datapoints in the context
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of other datapoints for that patient and in all cases found
one outlying data point not in line with other points for
that patient and clinically implausible, classifying these as
data entry errors versus the outlying extremes of real data.
Data were binned in 6-month intervals and pruned using
the modified Thompson-Tau algorithm (α = 1 × 10−4 for
height; α = 1 × 10−5 for weight) to identify and eliminate
any outliers (e.g., data-entry errors). To minimize the removal of real data, data belonging to a patient with greater
than three measurements were retained.
To facilitate the development of a smooth curve (i.e.,
no sudden model “dropoffs”) for the older pediatric age-
range and to evaluate final adult height, data from patients
19–25 years were also included in model development.
Datapoints greater than three SDs from the mean height
or weight of this older age group were removed.

Model development
The data were randomized (Figure 1). Models were developed on 90% of the data (training set); 10% of the data
were reserved for validation after model development.
The coefficients (e.g., a, p) of CDC growth functions5
were fit to the height and weight of children in our dataset. An iteratively reweighted least squares model, which
is a preferred model for data with increasing variability
(i.e., weight variance increases with age), was fitted using

an M-estimator by the nlrob function in the robustbase
package (version 0.93–8).9) in R Studio10 (1.4.1717 “Juliet
Rose,” R version 4.1.1) using the below equations and the
coefficients of the 50th percentile CDC growth curves for
children older than 2 years5 as starting parameters. When
model convergence could not be reached using these
starting parameters, a preliminary model was fitted by
the Levenberg-Marquadt algorithm (nlsLM function in
minpack.lm version 1.2-1 package11); the resulting coefficients were used as starting parameters for the iteratively
reweighted least squares model. Height is obtained as a
standing measurement (stature).
Ht (age) =

aq
1 + e−b1(age−c1)

+

ap
1 + e−b2(age−c2)

+

(f − a)
1 + e−b3(age−c3)

Wt (age) = a ∗ age10 (males) + b ∗ age9 + c ∗ age8 + d ∗ age7 + e ∗ age6
+ f ∗ age5 + g ∗ age4 + h ∗ age3 + i ∗ age2 + j ∗ age + k

To obtain well-fitted parameters, 100 × 5-fold cross
validation was used. In this process, the training set was
randomized into five approximately equally sized groups.
Four of the five groups (~80% of the training set) were
combined and model coefficients were fit to these data.
Then the coefficient of variation (CV) and root mean
squared error (RMSE) were calculated for the remaining
group’s data (~20% of the training set) fit to the model

F I G U R E 1 Model development scheme. The dataset was split (step 1) into training (90%) and validation sets (10%). The coefficients for
each model were parameterized for the training set using 100 × 5-fold cross validation (steps 2 and 3), and the performance of the validation
set on the final model was determined (step 4). CV, coefficient of variation; RMSE, root mean squared error
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described by the set of those coefficients. This process of
combining four of the five groups to determine the best-
fit model coefficients, and then testing how well the resulting model fits (using CV and RMSE) on the remaining
group, was repeated five times, with each group serving
once to test. The entire training set was then randomized
into five new, comparably sized groups, and the process
was repeated. In total, 100 dataset randomizations, each
split into five groups, were conducted (100 × 5-fold cross
validation). The means of the CV and RMSE for these 500
groups were calculated (Figure 1).
Because the height model is not additive, heights were
predicted for every model at 1-month intervals and averaged. A final model (as described above) was then fitted
through the average predicted heights. The coefficients
generated in 100 × 5-fold cross validation were averaged
for the final weight model.

Model performance
The CV and RMSE were calculated for the validation set
fit to the final model to establish how well this model
might perform on an external dataset. Growth model performance was assessed by comparing the RMSE and CV
between the training set and validation set. Similar errors
(RMSE and CV) between the training and validation sets
on the developed model indicate that the model is not
overfit to the data on which it was developed and, therefore, should be applicable to external datasets.

  

To compare the fit of actual data of patients with T2DM
to the CDC growth curves and the T2DM growth curves
developed in this study, the RMSE and CV of the validation set fitted to the 50th percentile CDC equations
and were compared to the errors of the validation set
for the T2DM-specific model. Larger values indicate a
poorer fit to the model. The final height of the model
output was compared with the final height of the CDC
50th percentile height-growth curves, and the means of
final height between 18.5 and 19 years (women) or 18.0
and 18.5 years (men, due to sample size) for the T2DM
dataset and the CDC dataset were compared using the
Student’s t-test.
Z-scores for the entire dataset, the number of SDs from
the CDC mean of height and weight for sex and age, were
calculated using an internal program.12 Z-scores were
binned in 6-month intervals and the mean, SD, and percent of patients with z-scores greater than 1 or less than
−1 were calculated.

915

Height-growth velocity
The velocity of T2DM height-growth was calculated as the
first-derivative of the final T2DM-specific height models—a
calculus-derived equation describing the rate-of-change of
height-growth as a function of age (cm/year).

RESULTS
The final dataset used to develop the T2DM growth model
included 211 women and 145 men (Table 1). There were
13 datapoints (of 12,602 total BMI datapoints) from 13 patients excluded as a result of BMI greater than 80 kg/m2; all
13 points were inconsistent with other BMIs reported for
the patients, clinically implausible points, and were thus
excluded as data-entry errors. Figure 2 shows the measured height or weight versus age and the model overlay.
Truncated versions of the final equations are as follows:
Male height (cm, age in years)
Ht =

(178 − 166)
166 ∗ 0.717
166 ∗ 0.283
+
+
−5.18(age−1.44)
−0.245(age−5.11)
1+e
1+e
1 + e−1.8(age−12.4)

Female height (cm, age in years)
Ht =

(209 − 160)
160 ∗ 0.604
160 ∗ 0.396
+
+
1 + e−0.537(age−2.23) 1 + e−0.0039(age−1.77) 1 + e−0.473(age−9.54)

TABLE 1

Comparison to CDC growth curves

|

Description of dataset
Female

Male

Number of training points

3973

2610

Number of validation points

458

306

Range

0–15

0–15.67

Mean (SD)

5.41 (4.43)

5.70 (4.55)

Range

1–230

1–199

Mean (SD)

21.62 (30.51)

20.53 (28.07)

Number of training points

5189

3350

Number of validation points

576

380

Range

0–15.49

0–15.67

Mean (SD)

6.13 (4.66)

6.17 (4.65)

Range

1–293

1–143

Mean (SD)

27.99 (39.97)

26.08 (34.83)

Height

Years of data per patient

Datapoints per patient

Weight

Years of data per patient

Datapoints per patient

916
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F I G U R E 2 Height or weight of children who develop type 2 diabetes mellitus versus age compared with patient-specific model of
growth (red) or the 50th percentile CDC model (blue). (a) height, females (b) height, males (c) weight, females (d) weight, males. Grey
symbols, training set; black symbols, testing set. Faint red lines correspond to the standard deviation, derived from the coefficient of
variation (%) of the datapoints from the model. CDC, Centers for Disease Control and Prevention

Male weight (kg, age in years)
Wt = 3.45 × 10−8 ∗ age10 − 4.58 × 10−6 ∗ age9
+ 2.61 × 10−4 ∗ age8 − 8.36 × 10−3 ∗ age7
+ 0.166 ∗ age6 − 2.12 ∗ age5 + 17.6 ∗ age4 − 92.6 ∗ age3
+ 294 ∗ age2 − 500 ∗ age + 358

Female weight (kg, age in years)
Wt = − 4.81 × 10−7 ∗ age9 + 5.00 × 10−5 ∗ age8
− 2.19 × 10−3 ∗ age7 + 0.0529 ∗ age6
− 0.770 ∗ age5 + 6.96 ∗ age4 − 38.7 ∗ age3
+ 128 ∗ age2 − 221 ∗ age + 164

The coefficients for weight reporting six significant
figures are in Supplemental Information S1. Due to the

high-degree polynomial, and some very small coefficients,
at least six significant figures appear to be needed in the
regression coefficients to accurately estimate the weights
as a function of age. This is in line with the CDC estimates
of weight at each percentile, which are reported to ten significant figures.5
The training and validation sets had similar CVs and
RMSEs, indicating that the growth model was not overfit
to the training data. The error rates (CV and RMSE) of
the height and weight of children who develop T2DM
fitted to the CDC model were substantially larger for
weight and marginally larger for height than when they
were fitted to T2DM growth models, indicating that CDC
growth models are less accurate in describing the growth
of children who develop T2DM (Table 2). Absolute residuals of the datapoints from the model, as well as
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percent error from the model are shown in Supplemental
Information S2. Heights and weights of children who
develop T2DM, as simulated in Simcyp version 2013
(n = 1000 simulations) using the reported equations and
%CV are shown in Supplemental Information S3, overlayed with the measured heights and weights in the reported dataset.
On average, children who develop T2DM were slightly
shorter (Figure 3) and substantially heavier than CDC
means (Figure 4). Mean height z-score was less than 0
(shorter than CDC average) in 30 of 34 (female children)
and 25 of 34 (male children) age bins. The scores greater
than 0 occurred between 8.5 and 11.5 years (female children) and 10.0–14.5 years (male children). A local peak
height velocity of T2DM growth curves (Figure 5) occurred at 8.5 years for female children, and 12.5 years for
male children. Ultimately, male and female children with
T2DM were shorter than CDC averages by 2 and 3 cm, respectively (both p < 0.01).5 Except for female children between 2 and 4.5 years of age, mean z-scores were greater
than 0 for weight. Weight z-score increased with age
(Spearman R = 0.911 [female children], 0.903 [male children], p < 0.0001). An exploratory analysis suggested that
there may be differences in growth depending on self-
reported race or ethnicity (Supplemental Information S4
and S5).

T A B L E 2 Fits of reference growth curves versus T2DM-specific
growth curve to data from T2DM children
Validation set fit to
growth model
CDC

T2DM

Model development
test set performance
(SD)

Coefficients of variation (%)
Height
Female

7.16

6.75

6.66 ± 0.15

Male

5.96

5.87

6.24 ± 0.21

Weight
Female

65.1

45.9

44.6 ± 0.92

Male

61.4

37.8

38.6 ± 1.11

Root mean squared error
Height
Female

9.89

9.33

9.21 ± 0.21

Male

8.4

8.27

8.87 ± 0.30

Weight
Female

37.4

26.3

24.8 ± 0.16

Male

36.6

22.6

23.3 ± 0.68

Abbreviations: CDC, United States Center for Disease Control; T2DM, type
2 diabetes mellitus.
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DISC USSION
Obesity is a significant risk factor in the development of
T2DM, and nearly all children who develop T2DM have
overweight or obesity. However, standardized growth patterns in youths with T2DM have not been developed and
the dataset presented here suggests that the most recent
2002 CDC-developed growth curves do not accurately
capture the pediatric T2DM growth trajectory. Despite
nearly one in five US children having obesity (i.e., BMI
>95th percentile for age and sex)—sometimes exceeding
BMI of 40 kg/m2 and/or the 99th percentile for age and sex
(class III obesity)—the CDC-developed pediatric growth
curves only capture a maximum BMI of 36 kg/m2 and the
97th percentile BMI for age and sex.5 As a result, there is
an inability to specifically describe or capture the growth
trajectory of children with severe obesity (about 20%
of our dataset, data not shown). Because most children
with T2DM have obesity, PBPK models incorporating
the CDC-growth chart data may not accurately simulate
pharmacokinetics in children with obesity/T2DM. Given
the challenges with recruiting and completing prospective clinical trials in children with T2DM,8 the use of
PBPK simulations could provide a vital tool for evaluating
drug disposition in this population. Thus, we developed
height and weight versus age growth curves analogous to
CDC growth curves, but specific to children who develop
T2DM.
Our data indicate there are deviations in the growth
patterns between youths ultimately diagnosed with
T2DM in childhood and typical healthy-weight growth
trajectories as described by the current CDC standard:
the errors (CV and RMSE) of the validation set fitted
to the CDC models were larger than when fitted to the
T2DM growth model. This observation supports the
premise that T2DM-specific growth curves are required
to accurately describe the growth of children who develop youth-onset T2DM and that these curves have the
potential to improve the accuracy of PBPK model predictions for these children during pharmacology trial
simulation.
Our data indicate that female children who developed
T2DM were below average weight during early childhood,
yet rapidly and consistently increased in weight z-score
beyond 4.5 years (Figure 3). Conversely, the male children
who developed T2DM were increasingly heavy relative to
CDC standards at all ages. Although we were unable to
evaluate birthweight, the observed patterns suggest that
some of these young female children with below average
weights may have been born with low birth weight and/
or small for gestational age (SGA), and could represent a
subset of the 15% of SGA children who do not catch up
by 2 years of age.14 Both low and high birthweight are

918
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F I G U R E 3 Top panels: CDC z-scores of height for T2DM children. (a) Female patients, and (b) male patients. Left y-axis: CDC z-score
of T2DM children (mean (bold lines) ± SD (faint lines)) binned into 6-month intervals. The grey box indicates one standard deviation above
and below the average CDC height (z = 0). Right y-axis: Bars represent the percent of T2DM children in the age bin with z-score greater
than 1 or less than −1. Bottom panels: Distribution of patient height z-scores greater than 1 (black bars), between −1 and 1 (white bars), and
less than −1 (grey bars). (c) Female patients, (d) male patients. The expected distribution if T2DM patients at each age and sex corresponded
to the CDC range would be that 15.9% of patients would fall below −1 (lower horizontal line), 68.2% would fall between the lines, and 15.9%
would be greater than 1 (upper horizontal line). CDC, Centers for Disease Control and Prevention; T2DM, type 2 diabetes mellitus

associated with the development of T2DM in adults, and
multiple studies have shown this association is stronger
in female compared to male children,15,16 supporting our
conclusions. The mechanism behind these sex-based differences is undetermined, although postulated to be due
to in utero sex hormones, particularly testosterone.16
Prior studies have shown that adults who develop
T2DM tend to experience rapid weight gain between 2 and
12 years of age.17,18 Our data indicate that this weight gain
may actually be prolonged until 16–17 years of age among
those with youth-onset T2DM. Because of the strong

association between overweight/obesity and T2DM, it is
plausible that this prolonged period of rapid weight gain
is representative of a more severe obesity phenotype, contributing to earlier onset of T2DM in pediatrics. The treatment of T2DM in our cohort may have also influenced
growth trajectories, especially if patients were treated
with insulin. Although insulin therapy is effective at improving glycemic control in diabetes, it is also associated
with weight gain.19 Information regarding patient-specific
treatments was beyond the scope of this dataset, yet it is
conceivable that insulin initiated for T2DM treatment

GROWTH PATTERNS IN YOUTH-ONSET T2DM
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F I G U R E 4 Top panels: CDC z-scores of weight for T2DM children. (a) Female patients, (b) male patients. Left y-axis: CDC z-score of
T2DM children (mean (bold lines) ± SD (faint lines)) binned into 6-month intervals. The grey box indicates one SD above and below the
average CDC weight (z = 0). Right y-axis: Bars represent the percent of T2DM children in the age bin with z-score greater than 1 or less than
−1. Bottom panels: Distribution of patient weight z-scores greater than 1 (black bars), between −1 and 1 (white bars), and less than −1 (grey
bars). (c) Female patients, (d) male patients. The expected distribution if T2DM patients at each age and sex corresponded to the CDC range
would be that 15.9% of patients would fall below −1 (lower horizontal line), 68.2% would fall between the lines, and 15.9% would be greater
than 1 (upper horizontal line). CDC, Centers for Disease Control and Prevention; T2DM, type 2 diabetes mellitus

may have impacted trends in weight gain among the study
population. Conversely, treatment with metformin is not
anticipated to contribute to rapid weight gain, and if anything may have curtailed the rapid weight gain captured
in our model, albeit with inconsistent success.20
The modest deviations observed in height were not anticipated. It was expected that the mean height z-scores
would approximate zero, similar to CDC growth curves.
Instead, both male and female children who developed
T2DM were—on average—shorter than expected as represented by CDC curves (z-score <0) during the majority

of their early childhood and later adolescence. Based on
our incorporation of continued T2DM growth trajectories
for young adulthood (i.e., 19–25 years), these children
ultimately achieved a shorter final adult height (3 cm
shorter in female patients, 2 cm shorter in male patients)
than expected from averages reported by the CDC. Robust
analysis of height-specific data among T2DM populations are lacking, although some studies suggest adults
with glucose intolerance and T2DM are modestly, but
significantly shorter than control subjects.21,22 One limitation of our deidentified dataset is the possibility that
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F I G U R E 5 Velocity of height growth per year. Left: female, right: male. The first derivative of the growth models. Grey dashed lines,
CDC; black lines, type 2 diabetes. CDC, Centers for Disease Control and Prevention

concomitant syndromic conditions associated with T2DM
and short stature (e.g., Turner syndrome and Prader Willi
Syndrome) were inadvertently included in this analysis, potentially skewing the final adult height results.
Variation in the racial/ethnic makeup of our population
compared to those used for CDC growth curves may have
also contributed to discrepancies in height. Indeed, an exploratory analysis revealed significant differences in the
heights and weights, as well as preliminary fitted curves
for children in our dataset based on self-identified race
(Supplemental Information S4). However, evidence suggests that children have similar growth potential, with
differences attributed to primarily environmental factors
versus genetic.5 Finally, differences in pubertal timing
may have impacted epiphyseal fusion, particularly in female patients, and thus impacted obtainment of the expected adult height, as discussed below.
One exception to the overall tendency toward shorter
stature for children who develop T2DM compared to CDC-
standards was from ages 8.5–11.5 years for girls and 10.0–
14.5 years for boys. During this time, thought to coincide
with puberty onset, T2DM-specific growth curves demonstrated taller stature than expected based on CDC curves.
We hypothesize this is related to slightly earlier timing of
the pubertal growth spurt. Indeed, a local peak height-
growth velocity occurred at 8.5 years for girls who develop
T2DM, and 12.5 years for boys who develop T2DM, which
is earlier than the accepted standard ages of pubertal
growth spurt 11–11.523–26 for healthy girls and 13–14 for
boys.23–26 Obesity27 and hyperinsulinemic insulin resistance28 may shift puberty earlier, which could potentially
result in the early growth spurt observed here. In female
patients, but not male patients, earlier growth spurts and
puberty28–30 are associated with decreased adult height.
Although this study was not designed to assess the
pubertal timeline, our data and others suggest the

potential for earlier puberty in children with T2DM.
Puberty is accompanied by behavioral changes that may
affect drug compliance and lifestyle (e.g., diet, exercise,
and illicit drug use), and is associated with increased
insulin resistance. Furthermore, puberty has the potential to affect pharmacokinetics31 by altering factors such
as plasma protein concentrations, fat distribution, and
high concentrations of sex steroids, and therefore may
affect the systemic exposure and distribution, and thus
effect of antidiabetic drugs and other therapeutics. An
earlier progression to puberty is therefore not trivial and
additional therapeutic and clinical monitoring may be
advisable based on our data.
The trends characterized in this study are important
for the development of PBPK models that accurately capture growth trajectories across the pediatric age range.
Nevertheless, our study has several limitations. First, our
findings are representative of a single regional pediatric
hospital, and variability in these trends will need to be
studied in a larger dataset, including other hospitals with
different patient demographics, local resources, regional
cultures, etc. Second, metformin—the first-line pharmaceutical treatment for children with T2DM—may ameliorate height deficits and delay puberty in children with
early puberty.28,29 We acknowledge that the introduction
of this necessary treatment has the potential to confound a
complete understanding of the effects of T2DM on pubertal timing. Additionally, while we suspect that our growth
models support a hypothesis of premature puberty, this
could not be confirmed by Tanner staging, given the nature of our dataset. The initiation of T2DM treatments,
(e.g., metformin and insulin) in this sample population
could confound a complete understanding of the effects
of T2DM on growth. Last, in the United States, after the
age of 2 years, weight is generally evaluated as a function
of stature (standing height), as opposed to age. However,
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pediatric PBPK models often report weight as a function
of age and thus our models were built to best represent the
input required for these models.
In summary, we have shown that the development of
T2DM during childhood or adolescence is associated with
growth patterns that deviate from those characterized by
CDC growth curves. As expected, children with T2DM
exhibited greater-than-average weights and prolonged duration of abnormal weight gain. Unexpectedly, children
who develop T2DM appear to attain a slightly shorter stature than their peers by adulthood, but may have an early
growth spurt, potentially due to earlier onset of puberty.
Further longitudinal research on larger populations will
be necessary to confirm these observations and to determine whether the observed differences in growth trajectories are similar across pediatric centers. PBPK simulations
of drug concentrations in children rely on scaling factors,
such as liver volume, which can be estimated for children
with normal weight, as well as obesity, as a function of
body surface area,2,3 which can be calculated with height
and weight. Therefore, reliable estimates of height and
weight may be critical to accurately estimating drug concentrations in the pediatric population of interest,32 and
the development of growth curves accurately reflecting
the pediatric patient population of interest is an essential
preliminary step in pediatric PBPK model development
when growth trajectories for the population differ substantially from typical healthy peers (e.g., children with
obesity and children who develop T2DM). Differences observed between the T2DM and CDC growth curves suggest
that disease conditions in children may deviate from the
“usual” patterns of growth, with potential implications for
modeling and simulation in those diseases (e.g., cerebral
palsy and cystic fibrosis). The use of disease-specific population growth curves should be considered for pediatric
drug development and model-informed precision dosing.
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